+

WO1995013383A1 - Procedes et reactifs pour l'allongement des telomeres - Google Patents

Procedes et reactifs pour l'allongement des telomeres Download PDF

Info

Publication number
WO1995013383A1
WO1995013383A1 PCT/US1994/013130 US9413130W WO9513383A1 WO 1995013383 A1 WO1995013383 A1 WO 1995013383A1 US 9413130 W US9413130 W US 9413130W WO 9513383 A1 WO9513383 A1 WO 9513383A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
telomeres
oligonucleotide
telomerase
Prior art date
Application number
PCT/US1994/013130
Other languages
English (en)
Inventor
Jerry Shay
Michael David WEST
Woodring E. Wright
Original Assignee
Geron Corporation
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/153,051 external-priority patent/US5645986A/en
Application filed by Geron Corporation, Board Of Regents, The University Of Texas System filed Critical Geron Corporation
Priority to AU13307/95A priority Critical patent/AU1330795A/en
Priority to PCT/US1994/013130 priority patent/WO1995013383A1/fr
Publication of WO1995013383A1 publication Critical patent/WO1995013383A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Definitions

  • This invention relates to methods and reagents for extending the telonieres and therefore the proliferative capacity of cells.
  • the invention therefore relates to the fields of chemistry, pharmacology, biology, molecular biology, and medical therapeutic and diagnostic technology.
  • Normal human somatic cells i.e., fibroblasts, endothelial, and epithelial cells
  • fibroblasts, endothelial, and epithelial cells display a finite replicative capacity of 50-
  • Cellular immortalization (the acquisition of unlimited replicative capacity) may be thought of as an abnormal escape from cellular senescence. See Shay et _ ⁇ _L 1991, Exp . Cell Res. 196:33. Normal human somatic cells appear to be mortal and to have finite replicative potential. In contrast, germline and malignant tumor cells appear to be immortal and to have indefinite proliferative potential. Human cells cultured i n vi tro appear to require the aid of transforming viral oncoproteins to become immortal, and even then, the frequency of immortalization is 10 " " " to 10 " ⁇ . See Shay and Wright, 1989, Exp . Cell Res . 184: 109. Cells obtained from murine sources immortalize at a relatively high frequency without the aid of transforming oncoproteins. A variety of hypotheses have been advanced over the years to explain the causes of cellular senescence.
  • the mortality stage 1 mechanism (M l ) is a mechanism by which cells cease to proliferate after a certain number of population doublings, and the biological molecules that carry out this mechanism appear to be the target of certain tumor virus proteins.
  • An independent mortality stage 2 mechanism (M2) produces crisis in cells that have bypassed M l , with crisis being typified by severe chromosomal abnormalities and ultimately cell death.
  • the M2 mechanism thus prevents tumor viruses from directly immortalizing human cells.
  • the papers noted above describe experiments in which T-antigen expression was driven by a mouse mammary tumor virus promoter to cause reversible immortalization of cells.
  • SV40 T-antigen extends the replicative life span of human fibroblasts by an additional 40-60%.
  • the M l mechanism is overcome by T-antigen, perhaps by binding to various cellular proteins or by inducing new activities to repress the Ml mortality mechanism.
  • the M2 mechanism then causes cessation of proliferation, even though the Ml mechanism is blocked. Immortality is achieved only when the M2 mortality mechanism is also disrupted.
  • the M2 mechanism appears to cause a dominant repression of the immortal phenotype, because hybrids between mortal and immortal human cells are generally mortal.
  • telomeres of human somatic cells act as a mitotic clock, shortening with age both in vitro and i n vi v o in a replication dependent manner and proposes a hypothesis for human cell aging and transformation in which telomeres and telomerase, a ribonucleoprotein polymerase involved in telomeric DNA synthesis, play a causal role in cell senescence and cancer.
  • PCT patent publication No. 93/23572 describes therapeutic and diagnostic methods relating to telomerase and telomere length.
  • the publication describes oligonucleotide reagents that either reduce loss of telomere length during passage of cells in. vi tro or increase telomere length of immortal cells in vitro.
  • the present invention provides a method for increasing the proliferative capacity of normal cells, which method comprises culturing or cultivating said cells in the presence of a therapeutically effective amount of an oligonucleotide substrate for telomerase under conditions such that said oligonucleotide substrate enters said cells and acts to lengthen telomeric DNA of said cells.
  • the therapeutic method of this invention postpones cellular senescence in cells, and is especially useful for cells expressing telomerase and for hybrids between immortal and mortal cells.
  • the method can also be used to reduce the level of chromosomal fusions and other chromosomal aberrations by increasing the telomere repeat length in cells.
  • the cells treated by the present method can be cultured or cultivated in. vivo during administration of the oligonucleotide
  • the invention has particular application to the cultivation of cells ex. vivo, and provides especially important benefits to therapeutic methods in which cells are cultured e x vivo and then reintroduced to a host.
  • Especially preferred examples of such cells include the CD4 + cells and the CD8+ cells of HIV-infected individuals and immune cells of aged people.
  • the method is also preferred for increasing the replicative capacity of hybrids between immortal and mortal human cells, such as hybrids between human B-lymphocytes and myeloma cells, to increase the replicative capacity of antibody producing human hybridomas.
  • the method of the invention is applicable to any normal cell type, the method can be practiced using normal cells that express a low level of telomerase activity.
  • the term "normal” refers to cells other than tumor cells, cancer calls, or transformed cells.
  • Especially preferred cells for use in the present method include embryonic, fetal, neonatal, and adult stem cells of any organ, and adult pluripotent hematopoietic stem cells.
  • the method can also be applied to immortalized or transformed cells, such as myeloma cells, to increase telomere length prior to hybridization with a mortal cell.
  • the reagents of the invention include any oligonucleotide substrate for telomerase.
  • the oligonucleotides of the invention can be composed of naturally occurring nucleotides or synthetic nucleotides or synthetic nucleotide analogs or combinations of any of the same. Typically, such oligonucleotides will be at least 12 nucleotides in length or longer.
  • Figure 1 shows the results of telomere length analysis
  • telomeres of IDH4 cells elongate by several kbp after 90 days of thrice weekly treatment in culture with 30 ⁇ M GTR (for "G-rich Telomeric Repeat") oligonucleotide (5'-TTAGGGTTAGGG-3'). Lanes 1, 3, 5, and 7 show the results for control, untreated cells.
  • Lane 2 shows the results for cells treated for 90 days with 30 ⁇ M GTR oligonucleotide.
  • Lane 4 shows the results for cells treated for 90 days with 30 ⁇ M GTR oligonucleotide and then cultured for 30 days in the absence of added GTR oligonucleotide.
  • Lane 6 shows the results for cells treated for
  • Lane 8 shows the results for cells treated for 90 days with 30 ⁇ M GTR oligonucleotide and then cultured for 90 days in the absence of added GTR oligonucleotide.
  • Figure 2 shows the results of telomere length analysis of IDH4 cells treated according to the method of the invention as well as control cells and shows that a progressive (up to 30 ⁇ M) dose response is observed with increasing concentrations of the GTR oligonucleotide.
  • Lane 1 shows the results for untreated control cells.
  • Lane 2 shows the results for cells treated for 90 days with 10 ⁇ M GTR oligonucleotide.
  • Lane 3 shows the results for cells treated for 90 days with 30 ⁇ M GTR oligonucleotide.
  • Lane 4 shows the results for cells treated for 90 days with 100 ⁇ M GTR oligonucleotide.
  • Figure 3 shows the results of telomere length analysis of a variety of different cells treated according to the method of the invention as well as control cells and shows that the effect of the GTR oligonucleotide is not restricted to a few immortal cell lines, because all of the cell lines tested responded to GTR oligonucleotide treatment by elongating their telomeres.
  • CAKl renal carcinoma cells increase the length of their telomeres approximately the same amount as the SW620 GTR-treated cells (lane 3, control, and lane 4, GTR- treated cells) under the same condtions.
  • DU145 prostatic adenocarcinoma cells and COLO205 colon carcinoma cells which have slightly longer telomeres in control (untreated) cells, also elongate their telomeres in the presence of GTR oligonucleotide (lanes 5 and 7, controls, and lanes 6 and 8, GTR-treated, respectively) under the same conditions.
  • telomeres DNA polymerase synthesizes DNA in a 5'-to-3' direction and requires a primer to initiate synthesis. Because of the mechanism of action of DNA polymerase, the "lagging strand" is not replicated to the very end of a linear chromosome, as there is no means to initiate synthesis at the end of this strand. The chromosome is thus shortened with every cell division.
  • telomeres comprise long stretches of duplex nucleic acid composed of a repeating sequence, called the "telomeric repeat," which in humans is 5'-TTAGGG-3 ⁇
  • the G- rich strand of the telomere is longer than the C-rich strand; consequently, telomeres also comprise a single-stranded region composed entirely of telomeric G-rich repeat sequences.
  • the enzyme telomerase is believed to mediate the synthesis of at least the terminal portion of the G-rich strand of the telomere.
  • the cellular senescence hypothesis is that somatic cells lack telomerase and so lack the ability to replicate the very ends of DNA molecules. This results in a progressive shortening of the ends of the chromosomes with each cell division until a point at which this progressive loss signals functional changes, at which time the cell loses the capacity to proliferate.
  • the term "senescence” refers to the loss of ability of a cell to replicate in the presence of normally appropriate mitogenic signals. Senescence is also typically accompanied by a change in expression patterns of one or more genes. For instance, senescence in some cells is accompanied by an increase in the expression of degradative enzymes, such as collagenase. The term senescence does not include quiescent cells that can be induced to re-enter the cell cycle under appropriate conditions.
  • telomere length is directly correlated to the life span of an individual cell. Certain populations of cells may lose telomere length at a greater rate than other cells within an individual, and those cells with shortened telomeres may thus become age-limiting within an individual organism. In such cases, important benefits can be achieved by slowing the loss of telomere sequences, which can be achieved by increasing the length of telomeric DNA.
  • the present invention provides a method for increasing the length of telomeres in normal cells and in hybrids between normal and immortal cells, thus extending the ability of a cell or hybrid to replicate and increasing the proliferative capacity of the treated cell.
  • a telomere- extending amount of an agent that increases telomere length within the cell is provided to the cell.
  • the telomeres within a particular cell population can be lengthened by provision of an oligonucleotide that acts to lengthen telomeres in cell culture or cultivation, thus increasing the number of cell divisions that can occur before a cell becomes senescent.
  • telomere lengthening by providing a nucleic acid, e.g., DNA or RNA (including modified forms), that can act as a telomerase substrate to the cells.
  • a nucleic acid e.g., DNA or RNA (including modified forms)
  • Such nucleic acids typically include at least 2 to 3 telomeric repeat sequences, which in humans is 5'-TTAGGG-3'.
  • This method is useful for the treatment of individuals not suffering from any particular condition but in which one or more cell types are limiting in that individual.
  • the method thus can be practiced to delay the onset of cell senescence, which, as noted above, is characterized by the inability of that cell to replicate further in an individual.
  • the method is a disease prevention method.
  • the present invention also provides important new methods for treating disease, especially diseases characterized by an increased rate of proliferation of one or more particular groups of cells. An increase in the rate of proliferation increases the rate at which telomeric DNA is lost and the rate at which cells become senescent.
  • the present method can be used to prevent the detrimental effects of early senescence of the cells due to increased cellular turnover associated with the disease.
  • the present invention also has application in tissue culture techniques to delay the onset of cellular senescence, whether for therapeutic or other purposes, such as manufacturing and research purposes.
  • tissue culture techniques to delay the onset of cellular senescence, whether for therapeutic or other purposes, such as manufacturing and research purposes.
  • many cell-based therapies require the clonal expansion of cells for later reintroduction into a patient. During the expansion process, however, the cells continue to approach the Hayflick limit, so the cells reintroduced to the patient may be senesecent or close (i.e., within a few divisions) to a senescent state.
  • This invention allows the expansion of cells in the presence of telomere lengthening agents and so provides a means to avoid the problems associated with cell senescence.
  • the present invention allows normal cells to be cultivated for extended doublings in vitro.
  • Cell therapy involves the isolation of healthy human cells, the expansion of those cells ex vivo, and the reinfusion of the expanded cells into a patient.
  • Cell therapy has application in the treatment of cancer and organ transplantation and many other disease states or conditions.
  • bone marrow therapy takes advantage of the fact that bone marrow, the major organ of the immune system, is responsible for production of various cells in the blood from hematopoietic stem cells.
  • hematological disorders such as anemia, leukemia, and lymphoma through bone marrow transplantation, in which bone marrow is removed from a donor (allogenic transplant) or a patient (autologous transplant) through general surgery, frozen and stored, and then transfused into the patient at a later date. Once transfused into the patient, the bone marrow cells gravitate to the bone marrow and engraft, eventually producing new blood cells either to increase the number of such cells in the anemic patient or to reconstitute the bop marrow destroyed as a result of chemotherapy or radiati therapy.
  • stem cell factor such as stem cell factor, G-CSF, erythropoietin, thrombopoietin, IL-3, IL-6, IL-
  • Such processes and therapies have been used not only for bone marrow transplantation but also for peripheral blood cell transplantation, replenishment of T cells in AIDS patients, replenishment of lymphocytes in Down's syndrome patients, replenishment of mature immune cells in aplastic anemia patients, and gene therapy.
  • Gene therapy techniques in this context involve the introduction of a genetic construct into explanted cells, expansion of the clones that have incorporated the genetic construct, and then reintroduction of the altered cells into the host (see PCT patent publication Nos. 94/12629, 94/1 2633 , 94/12649, and 94/12650).
  • the number of disease conditions that can be treated using such methods will increase. For instance, while bone marrow stem cells can be used to regenerate the various differentiated cells of the blood, embryonic and fetal stem cells can be used to regenerate the various differentiated cells of the entire body, offering many diverse applications of cell therapy.
  • the expansion of cells in culture involves many population doublings, however, so the cells obtained by cell therapy methods after expansion are much closer to senescence than the cells used to begin the process.
  • the present invention in conjunction with the expansion step, one can prevent the cells from a net loss of telomeric DNA by lengthening telomeres during the expansion process, while the cells retain the primitive stem cell phenotype and express telomerase activity.
  • the resulting cells are not any closer to senescence than the cells used to begin the process; in fact, the present method offers the possibility that the resulting cells may even have a greater replicative capacity than the cells used to begin the process.
  • the method of the invention can be applied to bone marrow stem cells, some of which express at least a low level of telomerase activity but have finite replicative capacity. Telomerase activity can be detected in cell-free extracts of dividing, cultured hematopoietic stem and early progenitor cells but not other more differentiated dividing cells.
  • numerous kinds of ex viv o cell therapies using bone marrow stem cells are currently practiced or under development, and the present method can readily be practiced in conjunction with such methods.
  • stem and hematopoietic cells e.g., chemotherapy or radiation therapy
  • a disease linked to an immune system undergoing replicative senescence e.g. normal aging, or cases where the immune system has been severely and chronically stressed, e.g., HIV infection
  • the disease creates a condition in which CD4 + cells are limiting, and death is caused by the early senescence of CD4 + cells and the resulting unchecked infections by pathogens that follow. It is important to note that such cells age, because the replicative rate of the CD4 + cells is increased as a result of HIV infection such that telomere attrition is caused at a greater rate than normal for such cells.
  • the present invention provides therapeutic agents that can be used to treat such diseases and also provides diagnostic procedures by which immune senescence can be detected and appropriate therapeutic protocols followed.
  • the present invention provides a therapeutic protocol in which CD4 + and/or CD8+ cells, or a population of cells containing or enriched for CD4+ and/or CD8+ cells, can be removed from the individual, preferably at an early stage when AIDS is first detected, stored in a bank, and then reintroduced after treatment with a telomere-Iengthening reagent of the invention, into the individual at a later stage, i.e., when that individual no longer has a protective amount of
  • CD4 + and/or CD8+ cells available.
  • an individual's life can be extended by a protocol involving continued administration of that individual's limiting cells at appropriate time points.
  • These appropriate points can be determined by following C D4 + and/or CD8+ cell senescence, or by determining the length of telomeres within such CD4 + and/or CD8+ cells (as an indication of when those cells will become senescent).
  • currently practiced methods include those in which T cells, such as killer T cells, are isolated from a patient and expanded in culture (sometimes after gene therapy to introduce universal receptors for HIV) prior to reintroduction into the patient.
  • the present invention can be used to lengthen the telomeres of such cells either directly or by treatment of a progenitor cells that is then cultured in vi tro under differentiating conditions or allowed to differentiate i n vivo.
  • pluripotent hematopoietic stem cells differentiate when grown in culture and that various stimulatory agents, such as cytokines and antigens, can be used to influence the differentiation process.
  • the present method can be practiced in conjunction with such methods to prepare high proliferative capacity cells of a particular type.
  • embryonic and fetal stem cells are totipotent or pluripotent and can be used to generate cells of any particular type (note that fibroblasts, liver cells, and keratinocytes can all be converted into muscle cells if transfected with vectors that express muscle differentiation factors such as myogenin and yoD).
  • muscle differentiation factors such as myogenin and yoD
  • many late fetal tissues such as muscle, lung, kidney, and adrenals, express telomerase activity and so are amenable to the telomere-Iengthening methods of the invention . Consequently, the use of totipotent stem cells or telomerase- positive fetal cells in the present method offers significant benefits to the treatment of disease, particularly diseases associated with aging.
  • the present invention can be applied to generate cells with high proliferative capacity of a variety of tissue types, including: (a) cells of the central nervous system, including astrocytes, endothelial cells, and fibroblasts, which are involved in such age-related diseases as Alzheimer's disease, Parkinson's disease, Huntington's disease, and stroke; (b) cells of the integument, including fibroblasts, sebaceous gland cells, melanocytes, keratinocytes, Langerhan's cells, and hair follicle cells, which are involved in age-related diseases of the integument, such as dermal atrophy, elastolysis and skin wrinkling, sebaceous gland hyperplasia, senile lentigo, graying of hair and hair loss, chronic skin ulcers, and age- related impairment of wound healing; (c) cells of the articular cartilage, such as chondrocytes, the senescence of which leads to the overexpression of the destructive proteins collagenase and a
  • cells of the bone such as osteoblasts, osteoclast progenitor cells, bone marrow stromal fibroblasts, and osteoprogenitor cells, which are involved in osteoporosis
  • cells of the immune system such as B and T lymphocytes, monocytes, neutrophils, eosinophils, basophils, NK cells and their respective progenitors, which are involved in age-related immune system impairment
  • cells of the vascular system including endothelial cells, smooth muscle, cells, and adventitial fibroblasts, which are involved in age-related diseases of the vascular system including atherosclerosis, calcification, thrombosis, and aneurysms
  • cells of the eye such as retinal pigmented epithelium, lens epithelial cells, iris muscle cells (myoblasts), and vascular endothelial cells, which are involved in loss of vision, i.e., age-related macular degeneration
  • muscle satellite such as retinal pigmented epithelium, lens
  • the present invention can therefore be applied to generate a variety of different cell types with high proliferative capacity.
  • practice of the method involves treating the cells with an olignucleotide substrate for telomerase.
  • substrates can be identified by their ability to serve as primers for telomerase- mediated nucleotide addition to the 3 '-end of the primer in an in vitro reaction.
  • the oligonucleotide reagents of the invention can be identified by the property of ability to serve as a substrate for telomerase, the method of the invention in no way requires that the oligonucleotides actually be extended by telomerase in the cell for telomeres to be lengthened.
  • telomeres The exact mechanism of action in vivo of the oligonucleotides is not known at this time and may involve titration of a repressor of telomerase or some other mechanism. Indeed, in one embodiment of the invention, no oligonucleotide substrate is required, and the method involves cultivating telomerase-positive cells under conditions where cell division is limited or completely inhibited for a period of time, typically several days to weeks and optionally months, sufficient for telomeres to be lengthened.
  • the cells are treated in culture with an oligonucleotide substrate for telomerase in amounts sufficient to lengthen the telomeres of the cells.
  • substrates include oligonucleotides that comprise a telomeric repeat sequence 5'-TTAGGG-3 ' .
  • oligonucleotides suitable for purposes of the present invention include the 9-, 12-, and 15-nucleotide versions of oligonucleotides that comprise the telomeric repeat sequence, i .e. , 5 ' -TTAGGGTTA-3 ' and 5 ' - TTAGGGTTAGGG-3' .
  • oligonucleotides that serve as telomerase substrates can also be employed, including the oligonucleotide 5'-TCGAGCACAGTT-3 ⁇ which corresponds to the junction of a healed broken chromosome from a patient with thalassemia, and 5'-(GXGXGX)2-3', in which X can be independently selected at each position from either T or A, i.e., 5'-GTGAGTGAGTGA-3 ⁇
  • Other oligonucleotide substrates for telomerase that can be used for purposes of the present invention have been described in the art or can readily be identified using assays described in the art; see, e.g., Morin, 3 October 1991 , Nature 353 :454-456.
  • IDH4 a line of T-antigen immortalized human lung fibroblasts
  • GTR oligonucleotide the GTR oligonucleotide described above.
  • IDH4 cells express telomerase activity and have very short telomeres.
  • Figure 1 shows that the telomeres of IDH4 cells elongate by several kbp after 90 days (about 30 population doublings) of treatment in culture with the GTR oligonucleotide.
  • This elongating effect can be seen both by the increasing size of the DNA resistant to digestion by restriction endonucleases (the "TRF” or “Terminal Restriction Fragment”) and by the increasing signal following hybridization to oligonucleotides containing telomeric repeats.
  • the effect is specific to the GTR oligonucleotide, because telomere elongation was not observed following treatment with either an oligonucleotide containing the complementary sequence (5'-CCCTAACCCTAA-3'), called the "CTR” or "C-rich telomeric repeat” oligonucleotide, or a comparably sized oligonucleotide with a randomly selected sequence.
  • the effect may be partially reversible, because IDH4 cells with elongated telomeres exhibited somewhat shorter telomeres when cultured in the absence of oligonucleotides ( Figure 1 , lane 8, off 90 days).
  • Figure 2 shows that a progressive (up to 30 ⁇ M) dose response is observed with increasing concentrations of the GTR oligonucleotide.
  • Figure 3 shows that the effect of the GTR oligonucleotide is not restricted to a few immortal cell lines, because all of the cell lines tested responded to GTR oligonucleotide treatment by elongating their telomeres.
  • SW620 human colon adenocarcinoma cells which grow much faster than IDH4 cells, rapidly and progressively elongated their telomeres in the presence of 30 ⁇ M GTR oligonucleotide. The elongation was a continuous process that increased with increasing time of treatment.
  • CAKl renal carcinoma cells increase the length of their telomeres approximately the same amount as the SW620 GTR-treated cells ( Figure 3, lane 3, control, and lane 4, GTR-treated cells).
  • DU 145 prostatic adenocarcinoma cells and COLO205 colon carcinoma cells which have slightly longer telomeres in control (untreated) cells, also elongate their telomeres in the presence of GTR oligonucleotide ( Figure 3, lanes 4-8).
  • telomere-Iengthening effect of the oligonucleotides can be observed in normal cells that express telomerase activity.
  • Methods for measuring telomerase activity have been described in the art (see, e.g., PCT patent publication No. 93/23572), and an especially preferred method is described in copending U.S . patent application Serial No. 08/315,214, filed 28 Sep. 1994 (Harley et al-)-
  • telomere length may aid the practitioner in determining whether treatment according to the present method is needed for a particular cell type and whether such treatment has been effective.
  • Procedures for measuring telomere length are known in the art. Typically, restriction endonuclease digestion is used (with enzymes which have a four-base recognition sequence, like HinfL and do not cleave telomeric
  • telomeric DNA sequences DNA sequences to cleave the genomic DNA; the cleaved fragments are separated according to molecular weight by agarose gel electrophoresis; and the gel is then dried and probed with a radioactively labelled probe, i.e. , 5 ' -(TTAGGG) 3 - 3 ' , complementary to telomeric DNA sequences.
  • a radioactively labelled probe i.e. , 5 ' -(TTAGGG) 3 - 3 ' , complementary to telomeric DNA sequences.
  • the oligonucleotides of the invention can be transferred into the cytoplasm of a cell spontaneously, i.e., without specific modification.
  • the cells may be permeabilized to enhance transport of the oligonucleotides into the cell without injuring the cells.
  • liposomes particularly where the liposome surface carries ligands specific for target cells or are targetted to a specific organ, one can provide for the introduction of an oligonucleotide into the target cells in. vivo .
  • lipocortin's affinity for phosphatidyl serine which is released from injured vascular endothelial cells
  • catheters, syringes, depots, or the like can be used to provide high localized concentrations of an oligonucleotide in vivo.
  • compositions that include therapeutically effective amounts of the agents described above in pharmaceutically acceptable buffers.
  • These pharmaceutical compositions can include one or more of these agents and be co-administered with other drugs.
  • Compositions and products according to the invention may conveniently be provided in the form of solutions suitable for parenteral, nasal, or oral administration. In many cases, it will be convenient to provide an agent in a single solution for administration.
  • Amphoteric agents may be utilized as free bases, as acid addition salts, or as metal salts.
  • the salts must, of course, be pharmaceutically acceptable, and these will include metal salts, particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts .
  • metal salts particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts .
  • a wide variety of pharmaceutically acceptable acid addition salts are available. These include those prepared from both organic and inorganic acids, preferably mineral acids. Typical acids that may be mentioned by way of example include citric, succinic, lactic, hydrochloric, and hydrobromic acids. Such products are readily prepared by procedures well known to those skilled in the art.
  • the agents of the invention can be provided as parenteral compositions for injection or infusion.
  • the agents can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, or olive oil.
  • the agents can be suspended in an aqueous isotonic buffer solution at a pH of about 5.6 to 7.4.
  • Useful buffers include sodium citrate-citric acid and sodium phosphate- phosphoric acid.
  • the desired isotonicity can be achieved using sodium chloride or other pharmaceutically acceptable agents, such as dextrose, boric acid, sodium tartrate, propylene glycol, or other inorganic or organic solutes.
  • Sodium chloride is preferred for buffers containing sodium ions.
  • solutions of the above compositions can be thickened with a thickening agent such as methyl cellulose.
  • the solutions can be prepared in emulsified form, either water in oil or oil in water.
  • emulsifying agents can be employed, including, for example, acacia powder or an alkali polyether alcohol sulfate or sulfonate.
  • compositions of the invention are prepared by mixing the ingredients following generally accepted procedures.
  • the selected components can be simply mixed in a blender or other standard device to produce a concentrated mixture that can then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
  • compositions can be provided in dosage unit form containing an amount of agent that will be effective in one or multiple doses to perform the desired function.
  • an effective amount of therapeutic agent will vary with many factors, including the age and weight of the patient, the patient's physical condition, and other factors.
  • Selected agents e.g., oligonucleotides and pharmaceutical compositions of the same, can be administered prophylactically or to patients suffering from disease, e.g., by exogenous delivery of the agent to an infected tissue by means of an appropriate delivery vehicle, e.g., a liposome, a controlled release vehicle, by use of iontophoresis, electroporation, or ion-paired molecules, or covalently attached adducts, and other pharmacologically approved methods of delivery.
  • routes of administration include intramuscular, aerosol, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal, and/or intrathecal.
  • Gene therapy administered using recombinant expression vectors encoding a therapeutic oligonucleotide of the invention can also be used to deliver an oligonucleotide to a cell.
  • the specific delivery route of any selected agent will depend on the use of the agent. Generally, a specific delivery program for each agent will focus on naked agent uptake with regard to intracellular localization, followed by demonstration of efficacy. Alternatively, delivery to the same cells in an organ or tissue of an animal can be accomplished. Uptake studies can include uptake assays to evaluate cellular oligonucleotide uptake, regardless of the delivery vehicle or strategy. Such assays will also determine the intracellular localization of the agent following uptake, ultimately establishing the requirements for maintenance of steady-state concentrations within the cellular compartment containing the target sequence (nucleus and/or cytoplasm). Efficacy and cytotoxicity can also be tested. Toxicity studies will address not only cell viability but also cell function.
  • Some methods of delivery suitable for oligonucleotides include: encapsulation in liposomes ; transduction by retro viral vectors; and conjugation with agents that direct delivery to certain sites withing the body.
  • At least three types of delivery strategies are useful in the present invention, including: agent modification, particle carrier delivery vehicles, and retroviral expression vectors .
  • Unmodified agents may be taken up by cells slowly and inefficiently.
  • an agent can be modified to reduce charge but maintain specific functional groups to improve diffusion across the cell membrane. Modification of agents to reduce charge is one approach to enhance the cellular uptake of these larger molecules.
  • the structural requirements necessary to maintain agent activity are well understood by those in the art. These requirements are taken into consideration when designing modifications to enhance cellular delivery.
  • the modifications are also designed to reduce susceptibility to enzymatic degradation. Both of these characteristics should greatly improve the efficacy of the agent. Chemical modifications of the phosphate backbone of oligonucleotides will reduce the negative charge, allowing free diffusion of the oligonucleotide across the membrane .
  • oligonucleotides In the body, maintenance of an external concentration is necessary to drive the diffusion of the modified oligonucleotides into the cells of the tissue.
  • Administration routes that allow the diseased tissue to be exposed to a transient high concentration of the oligonucleotide, which is slowly dissipated by systemic adsorption, can be used.
  • Intravenous administration with a drug carrier designed to increase the circulation half-life of the oligonucleotides can also be used.
  • the size and composition of the drug carrier restricts rapid clearance from the blood stream.
  • the carrier made to accumulate at the site of infection, can protect the oligonucleotides from degradative processes.
  • Drug delivery vehicles are effective for both systemic and topical administration.
  • the vehicles can be designed to serve as a slow release reservoir or to deliver their contents directly to the target cell.
  • An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake.
  • Such vehicles have been shown to increase the circulation half-life of drugs that would otherwise be rapidly cleared from the blood stream.
  • Some examples of such specialized drug delivery vehicles that fall into this category are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
  • nanoparticles and hydrogels have been used as delivery vehicles for chemotherapeutic agents and protein- based pharmaceuticals. Liposomes increase extracellular stability, increase uptake efficiency and improve biological activity.
  • Liposomes are hollow spherical vesicles composed of lipids arranged in a similar fashion as those lipids that make up the cell membrane. Liposomes have an internal aqueous space for entrapping water soluble compounds and range in size from
  • liposomes can deliver agents to cells in biologically active form.
  • a liposome delivery vehicle originally designed as a research tool, lipofectin has been shown to deliver intact mRNA molecules to cells yielding production of the corresponding protein.
  • Liposomes offer several advantages : liposomes are non-toxic and biodegradable in composition; liposomes display long circulation half-lives; and recognition molecules can be readily attached to liposome surfaces for targetting to tissues.
  • cos t effecti ve m anufacture of lipos ome-b ased pharmaceuticals, either in a liquid suspension or lyophilized product has demonstrated the viability of this technology as an acceptable drug delivery system.
  • Topical administration of agents is advantageous, because topical administration allows localized concentration at the site of administration with minimal systemic adsorption. This simplifies the delivery strategy of the agent to the disease site and reduces the extent of toxicological characterization. Furthermore, the amount of material to be applied is far less than that required for other administration routes. Effective delivery requires the agent to diffuse into the target cells. Chemical modification of the agent to neutralize negative or positive charges can in some instances enhance penetration.
  • the modified agent can also be co- formulated with permeability enhancers, such as azone or oleic acid, in a liposome.
  • the liposomes can either represent a slow release presentation vehicle in which the modified agent and permeability enhancer transfer from the liposome into the targeted cell, or the liposome phospholipids can participate directly with the modified agent and permeability enhancer in facilitating cellular delivery.
  • both the agent and permeability enhancer can be formulated into a suppository formulation for slow release.
  • Agents can also be systemically administered.
  • Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body.
  • Administration routes which lead to systemic absorption include: intravenous, subcutaneous, intraperitoneal, intranasal, intrathecal, and ophthalmic. Each of these administration routes exposes the agent to an accessible diseased or other tissue.
  • Subcutaneous administration drains into a localized lymph node and proceeds through the lymphatic network into the circulation. The rate of entry into the circulation has been shown to be a function of molecular weight and size.
  • the use of a liposome or other drug carrier localizes the agent at the lymph node.
  • the agent can be modified to diffuse into the cell, or the liposome can directly participate in the delivery of either the unmodified or modified agent to the cell.
  • delivery methods include liposomes, hydrogels, controlled-release polymers, microinjection, electroporation (for e x v i v o treatments), and other pharmaceutically applicable methods.
  • the dosage will depend upon the disease indication and the route of administration but can be between 10-2000 mg/kg of body weight/day.
  • the duration of treatment will extend through the course of the disease symptoms, usually at least 14- 16 days and in some indications continuously. Multiple daily doses are anticipated for topical applications, ocular applications, and vaginal applications.
  • the number of doses will depend upon delivery vehicle and efficacy data from clinical trials. Establishment of therapeutic levels of agent within the target cell is dependent upon the rate of uptake and degradation. Decreasing the degree of degradation will prolong the intracellular half-life of the agent.
  • chemically modified agents e.g., oligonucleotides with modification of the phosphate backbone, or capping of the 5' and 3' ends of the oligonucleotides with nucleotide analogues
  • the method may be applied to cells of any source, particularly cell of animals such as primates and domestic animals such as equine, bovine, avian, ovine, porcine, feline, and canine animals.
  • Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
  • the following examples are offered by way of illustration and not by way of limitation . Examples
  • Figs. 1 - 3 cells were incubated in regular culture medium containing serum in the presence of 10 ⁇ M, 30 ⁇ M, and 100 ⁇ M GTR oligonucleotide.
  • the cells were fed fresh phosphodiester GTR oligonucleotide thrice weekly and subcultured when confluent for a total of 90 days.
  • the cells were still growing in GTR oligonucleotide after 90 days at all concentrations used.
  • the IDH4 cells were shown have increased TRF length in a dose dependent manner with 30 ⁇ M and 100 ⁇ M having approximately the same effect.
  • the control and 30 ⁇ M GTR oligonucleotide-treated cells were passaged without oligonucleotide addition for an additional 90 days (approximately 35-40 PDL).
  • the TRFs slowly shorten.
  • Figure 1 shows that the telomeres of IDH4 cells elongate by several kbp after 90 days (about 30 population doublings) of treatment in culture with the GTR oligonucleotide.
  • This elongating effect can be seen both by the increasing size of the DNA resistant to digestion by restriction endonucleases and by the increasing signal following hybridization to oligonucleotides containing telomeric repeats.
  • the effect is specific to the GTR oligonucleotide, because telomere elongation was not observed following treatment with either an oligonucleotide containing the complementary sequence, or a comparably sized oligonucleotide with a randomly selected sequence.
  • the effect may be partially reversible, because IDH4 cells with elongated telomeres exhibited somewhat shorter telomeres when cultured in the absence of oligonucleotides ( Figure 1 , lane 8, off 90 days).
  • Figure 2 shows that a progressive (up to 30 ⁇ M) dose response is observed with increasing concentrations of the GTR oligonucleotide.
  • Figure 3 shows that the effect of the GTF oligonucleotide is not restricted to a few immortal cell line because all of the cell lines tested responded to G' oligonucleotide treatment by elongating their telomf
  • SW620 human colon adenocarcinoma cells which grow faster than IDH4 cells rapidly and progressively elo their telomeres in the presence of 30 ⁇ M GTR oligonur The elongation was a continuous process that increa increasing time of treatment.
  • C carcinoma cells increase the length of their approximately the same amount as the SW620 cells ( Figure 3, lane 3, control, and lane 4, GTP).
  • COLO205 colon carcinoma cells which have telomeres in control (untreated) cells, al? telomeres in the presence of GTR oligonucleotide ( Figure 3, lanes 4-8).
  • telomere length determines the lifespan of cells.
  • Cell hybrids were constructed between normal diploid BJ foreskin fibroblasts and either (1) immortal IDH4 cells; or (2) immortal IDH4 cells with telomeres elongated by the method of the present invention. Young BJ cells with approximately 60 doublings left in their normal i_n vitro lifespan were used to ensure that the normal telomeres would not be limiting for the hybrid lifespan. Fifty clones from each combination were picked and followed to determine their proliferative capacity. The loss of a few normal chromosomes from these hybrids can potentially result in the generation of immortal segregants.
  • the hybrid clones were maintained at low population sizes by serial clonal subcultivation. At each passage, the dishes were scanned, and an average sized clone was picked and replated. Cell counts of parallel dishes of the population of hybrids plated at clonal density indicated that each passage corresponded to approximately 13- 14 cell divisions.
  • the comparison of the lifespan of the two hybrids was repeated using a protocol desinged to determine the lifespan of populations of clones.
  • Hybrids were plated at clonal density in duplicate. After clones had formed, one dish was fixed and counted to determine the number of clones per dish, and one dish was trypsinized and counted to determine the number of cells per dish and then replated to form the next generation of subclones. This permitted the number of cells per clone and thus the average nubmer of cell divisions per passage to be determined. Because dishes containing 100-300 clones were used, the results represent the average of a large number of clones.
  • an immortal human cell such as a myeloma cell
  • telomere length is treated according to the method of the present invention to increase telomere length and then fused to a human antibody- producing cell.
  • the resulting cell hybrids have increased proliferative capacity as compared to human hybridoma cells made by methods currently available in the art.
  • telomere length by modulating telomere length, one may increase the proliferative capacity of cells and therefore treat disease and disease conditions associated with cellular senescence.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procédé et des compositions pour l'augmentation de la longueur des télomères de cellules normales peuvent être utilisés pour accroître la capacité de prolifération des cellules afin de retarder l'apparition de la sénescence cellulaire.
PCT/US1994/013130 1993-11-12 1994-11-10 Procedes et reactifs pour l'allongement des telomeres WO1995013383A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU13307/95A AU1330795A (en) 1993-11-12 1994-11-10 Methods and reagents for lengthening telomeres
PCT/US1994/013130 WO1995013383A1 (fr) 1993-11-12 1994-11-10 Procedes et reactifs pour l'allongement des telomeres

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/153,051 US5645986A (en) 1992-05-13 1993-11-12 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US08/153,051 1993-11-12
US08/151,477 1993-11-12
PCT/US1994/013130 WO1995013383A1 (fr) 1993-11-12 1994-11-10 Procedes et reactifs pour l'allongement des telomeres

Publications (1)

Publication Number Publication Date
WO1995013383A1 true WO1995013383A1 (fr) 1995-05-18

Family

ID=26788507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013130 WO1995013383A1 (fr) 1993-11-12 1994-11-10 Procedes et reactifs pour l'allongement des telomeres

Country Status (1)

Country Link
WO (1) WO1995013383A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001614A3 (fr) * 1994-07-07 1996-02-29 Cold Spring Harbor Lab Composant d'arn de la telomerase
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5856096A (en) * 1995-09-20 1999-01-05 Ctrc Research Foundation Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US6013468A (en) * 1994-07-07 2000-01-11 Cold Spring Harbor Laboratory RNA component of telomerase
US6294332B1 (en) 1996-07-01 2001-09-25 Telogene Inc. Composition and methods for modulating the length of telomeres
EP1207196A1 (fr) * 2000-10-27 2002-05-22 Societe Des Produits Nestle S.A. Preosteoblastes immortalisees et leurs procede de production
WO2002010352A3 (fr) * 2000-08-02 2003-02-27 Whitehead Biomedical Inst Production d'anticorps monoclonaux humains
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2020071652A1 (fr) * 2018-10-02 2020-04-09 주식회사 스템온 Procédé d'allongement de telomère cellulaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023572A1 (fr) * 1992-05-13 1993-11-25 University Of Texas Southwestern Medical Center At Dallas Therapie et diagnostic des etats pathologiques lies a la longueur du telomere et/ou a l'activite de la telomerase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023572A1 (fr) * 1992-05-13 1993-11-25 University Of Texas Southwestern Medical Center At Dallas Therapie et diagnostic des etats pathologiques lies a la longueur du telomere et/ou a l'activite de la telomerase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLSOPP, R. ET AL.: "TELOMERE LENGTH PREDICTS REPLICATIVE CAPACITY OF HUMAN FIBROBLASTS.", PROC NATL ACAD SCI U S A 89 (21). 1992. 10114-10118 *
BLACKBURN, E. ET AL.: "Recognition and elongation of telomeres by telomerase", GENOME, vol. 31, pages 553 - 560 *
HARLEY, C. B.: "TELOMERE LOSS MITOTIC CLOCK OR GENETIC TIME BOMB?.", MUTAT RES 256 (2-6). 1991. 271-282 *
KLINGELHUTZ, A. ET AL.: "Restoration of telomeres in human papillomavirus- immortalized human anogenital epithelial cells.", MOLECULAR AND CELLULAR BIOLOGY 14 (2). 961-969 *
VAZIRI H ET AL: "Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91 (21). 1994. 9857-9860. ISSN: 0027-8424 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876979A (en) * 1994-07-07 1999-03-02 Cold Spring Harbor Laboratory RNA component of mouse, rat, Chinese hamster and bovine telomerase
US6013468A (en) * 1994-07-07 2000-01-11 Cold Spring Harbor Laboratory RNA component of telomerase
WO1996001614A3 (fr) * 1994-07-07 1996-02-29 Cold Spring Harbor Lab Composant d'arn de la telomerase
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5916752A (en) * 1994-10-20 1999-06-29 Arch Development Corporation Telomerase screening methods
US6387619B1 (en) 1994-10-20 2002-05-14 Arch Development Telomerase compositions and methods
US5856096A (en) * 1995-09-20 1999-01-05 Ctrc Research Foundation Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US6294332B1 (en) 1996-07-01 2001-09-25 Telogene Inc. Composition and methods for modulating the length of telomeres
WO2002010352A3 (fr) * 2000-08-02 2003-02-27 Whitehead Biomedical Inst Production d'anticorps monoclonaux humains
EP1207196A1 (fr) * 2000-10-27 2002-05-22 Societe Des Produits Nestle S.A. Preosteoblastes immortalisees et leurs procede de production
WO2002034891A3 (fr) * 2000-10-27 2002-12-12 Nestle Sa Pre-osteoblastes immortalises et procede de production
US7202082B2 (en) 2000-10-27 2007-04-10 Nestec S.A. Immortalized preosteoblasts and method for their production
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9951389B2 (en) 2012-11-30 2018-04-24 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2020071652A1 (fr) * 2018-10-02 2020-04-09 주식회사 스템온 Procédé d'allongement de telomère cellulaire
US12241056B2 (en) 2018-10-02 2025-03-04 Stemon Inc. Method for extending telomere of cell

Similar Documents

Publication Publication Date Title
US5686306A (en) Methods and reagents for lengthening telomeres
JP7408284B2 (ja) 単純ヘルペスウイルスを治療するためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物
CN102712926B (zh) 用于抑制基因表达的组合物及其用途
US9999589B2 (en) Culture medium of adipose-derived stem cell, method for preparing the same, and composition including the same for promoting hair growth
WO1992022303A1 (fr) INHIBITION SELECTIVE DE LA PROLIFERATION DES CELLULES LEUCEMIQUES PAR DES OLIGONUCLEOTIDES ANTI-CODANTS $i(BCR-ABL)
CN112662674A (zh) 靶向编辑VEGFA基因外显子区域的gRNA及其应用
WO1995013383A1 (fr) Procedes et reactifs pour l'allongement des telomeres
EP0668782B1 (fr) Combinaison d'un agent anti-neoplasique et d'oligonucleotides antisens dans le traitement du cancer
US7601344B2 (en) Host cells obtained by introducing and expressing VHL gene in cancer cells or embryonic stem cells
CA3138030A1 (fr) Procedes de selection auxotrophe
WO1994023755A1 (fr) Nouveaux procedes et compositions destines au traitement du cancer active par ras au moyen d'oligonucleotides heterotypiques anti-raf et antisens
US20210052741A1 (en) Gene therapy methods and compositions using auxotrophic regulatable cells
CA2743828C (fr) Procedes cibles sur des recepteurs fas/fasl ou autres recepteurs de mort et compositions destines a eliminer des cellules tumorales
CN115052971A (zh) 在低氧条件下具有高适应性的细胞及其用途
WO2005058362A2 (fr) Procede d'ouverture de jonctions serrees
US20090304640A1 (en) Transfection of Collagen-Producing Cells
WO2022052909A1 (fr) Procédé d'édition du gène bcl11a dans des cellules souches/progénitrices hématopoïétiques
JP2022531930A (ja) 栄養要求性調節可能な細胞を使用する方法および組成物
CN116987666A (zh) 靶向sting通路制备治疗性nk细胞

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载